ZC9

ZC9 is a novel androgen receptor (AR) degrader. ZC9 directly binds to AR and inhibits Dihydrotestosterone-induced nuclear translocation of AR. ZC9 promotes AR degradation via the ubiquitin-proteasome system and suppresses AR transcriptional activity. ZC9 significantly decreases the mRNA levels of other AR downstream genes, including PSA, TMPRSS2, and PMEPA1. ZC9 promotes Apoptosis. ZC9 exhibits anticancer activity against prostate cancer[1].

Product Specifications

CAS Number

[2757513-79-2]

UNSPSC

12352005

Target

Androgen Receptor; Apoptosis

Related Pathways

Apoptosis; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer

Smiles

O=C(C1=CC=C(C=C(OCC2=C(C)ON=C2C)C=C3)C3=C1)NC4=NC(C5=CC=CS5)=CS4

Molecular Formula

C24H19N3O3S2

Molecular Weight

461.56

References & Citations

[1]Ji Y, et al. Cell-ELISA-Based High-Throughput Screening Leads to the Discovery of Androgen Receptor Degraders to Conquer Castration-Resistant Prostate Cancer. FASEB J. 2025 Oct 31;39 (20) :e71150.